Research Achievements
Koutaro Yokote| 2012 | 2011 | 2010 |
| Papers| International Conferences |
Papers
Takada-Watanabe A‚ Yokote K‚ Takemoto M‚ Fujimoto M‚ Irisuna H‚ Honjo S‚ Futami K‚ Furuichi Y‚ Saito Y. A case of Werner syndrome without metabolic abnormality: Implications for the early pathophysiology
Geriatrics and Gerontology International 2011; 12 140-146
Tamori‚ Y.‚ Takahashi‚ T.‚ Nakajima‚ S.‚ Nishimoto‚ Y.‚ Ohno‚ K.‚ Takemoto‚ M.‚ Yokote‚ K.‚ Tsutsumi‚ M. A case of Werner syndrome with compound heterozygous mutations of WRN gene.
The Journal of the Japanese Society of Internal Medicine 2011; 100 (1642): 1644-
Oshima Y‚ Kinouchi K‚ Ichihara A‚ Sakoda M‚ Kurauchi-Mito A‚ Bokuda K‚ Narita T‚ Kurosawa H‚ Sun-Wada GH‚ Wada Y‚ Yamada T‚ Takemoto M‚ Saleem MA‚ Quaggin SE‚ Itoh H. Prorenin receptor is essential for normal podocyte structure and function.
Journal of the American Society of Nephrology 2011; Dec (22): 2203-2212
Tsukamoto S‚ Takeuchi M‚ Kawajiri C‚ Tanaka S‚ Nagao Y‚ Sugita Y‚ Yamazaki A‚ Kawaguchi T‚ Muto T‚ Sakai S‚ Takeda Y‚ Ohwada C‚ Sakaida E‚ Shimizu N‚ Yokote K‚ Iseki T‚ Nakaseko C. Posterior reversible encephalopathy syndrome in an adult patient with acute lymphoblastic leukemia after remission induction chemotherapy.
Int J Hematol 2011;
Shibuya K‚ Misawa S‚ Horikoshi T‚ Kanai K‚ Isose S‚ Nasu S‚ Sekiguchi Y‚ Noto Y‚ Fujimaki Y‚ Nakaseko C‚ Kuwabara S. Detection of Bone Lesions by CT in POEMS Syndrome.
Intern Med 2011; 50 (13): 1393-1396
Usui N‚ Takeshita A‚ Nakaseko C‚ Ohwada C‚ Dobashi N‚ Fujita H‚ Kiyoi H‚ Kobayashi Y‚ Miyazaki Y‚ Ohtake S‚ Miyawaki S‚ Ohno R‚ Naoe T‚ Ohnishi K. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult AML -JALSG-AML206 study.
Cancer Sci. 2011; 102 (7): 1358-1365
Yokote‚ K.‚ Shimano H‚ Urashima M‚ Teramoto T Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis.
Expert Rev Cardiovasc Therapy 2011; 9 (5): 555-562
Tsurutani Y‚ Fujimoto M‚ Takemoto M‚ Irisuna H‚ Koshizaka M‚ Onishi S‚ Ishikawa T‚ Mezawa M‚ He P‚ Honjo S‚ Maezawa Y‚ Saito Y‚ Yokote K The roles of transforming growth factor-¦Â and Smad3 signaling in adipocyte differentiation and obesity.
Biochem Biophys Res Commun 2011; 407 68-73
Tanaka A‚ Sakurai K‚ Kaneko K‚ Ogino J‚ Yagui K‚ Ishikawa K‚ Ishibashi T‚ Matsumoto T‚ Yokote K‚ Saito Y. The role of the HIF-1 binding site in the induction of aquaporin-1 mRNA expression by hypoxia.
DNA Cell Biolog 2011; 30 539-544
Kawaguchi T‚ Tsukamoto S‚ Ohwada C‚ Takeuchi M‚ Muto T‚ Tanaka S‚ Sakai S‚ Takeda Y‚ Abe D‚ Sakaida E‚ Shimizu N‚ Yokote K‚ Iseki T‚ Imadome K‚ Nakaseko C. Successful treatment with rituximab and donor lymphocyte infusions for fulminant EBV-associated lymphoproliferative disorder that developed 14 years after unrelated BMT.
Bone Marrow Transplant 2011; 46 (12): 1583-1585
Muto T‚ Takeuchi M‚ Kawaguchi T‚ Tanaka S‚ Tsukamoto S‚ Sakai S‚ Takeda Y‚ Abe D‚ Ohwada C‚ Sakaida E‚ Shimizu N‚ Yokote K‚ Iseki T‚ Nakaseko C. Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogeneic hematopoietic stem cell transplantation.
Bone Marrow Transplant 2011; 46 (12): 1573-1575
Nakaseko C‚ Ozawa S‚ Sakaida E‚ Sakai M‚ Kanda Y‚ Oshima K‚ Kurokawa M‚ Takahashi S‚ Ooi J‚ Shimizu T‚ Yokota A‚ Yoshiba F‚ Fujimaki K‚ Kanamori H‚ Sakai R‚ Saitoh T‚ Sakura T‚ Maruta A‚ Sakamaki H and Okamoto S. Incidence‚ risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation.
Int J Hematol 2011; 93 (3): 375-382
Muto T.‚ Takeuchi M.‚ Kawaguchi T.‚ Tanaka S.‚ Tsukamoto S.‚ Sakai S.‚ Takeda Y.‚ Yokote K.‚ and Nakaseko C. Low-dose trimethoprim-sulfamethoxazole for Pneumocystis jiroveci pneumonia prophylaxis after allogenic hematopoietic SCT.
Bone Marrow Transplantation 2011; 46 (12): 1573-1575
Tanaka A‚ Sakurai K‚ Kaneko K‚ Ogino J‚ Yagui K‚ Ishikawa K‚ Ishibashi T‚ Matsumoto T‚ Yokote K‚ Saito Y. The role of the HIF-binding site in the induction of aquaporin-1 mRNA expression by hypoxia
DNA and Cell Biology 2011; 30 (8): 539-544
International Conferences
Yokote‚K. Studies on normal aging and progeric disorders
Conference on Ageing Societies – a Japanese-Swedish Research Cooperation¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡ 2011-9-22 Uppsala/Sweden
Ishikawa‚T. "R3h¡İDomain Containing Like Protein Is a Novel Regulator of Glomerular Basement Membrane. "
EASD¡§European Association for the Study of Diabetes (Âè47²ó²¤½£ÅüǢɳزñµÄ) 2011-9-12 Lisbon/Portugal
Sakurai‚K. Effect of an ¦Á-glucosidase inhibitor acarbose on glucagon-like peptide-1 secretion and postprandial lipid profile
"The 3rd Annual Scientific Meeting of the Asian Association for the Study of Diabetes" 2011-7-22 Beijing/China
Yokote K Pitavastatin: Eight years of successful lipid management
European Atherosclerosis pre-symposium 2011-6-25 Gothenburg/Sweden
Yokote K Statin in treatment of metabolic syndrome
The Royal College of Physician of Thailand 2011-4-29 Pattaya/Thailand
Naomi Shimizu‚ Chiaki Nakaseko‚ Masahiro Takeuchi‚ Chikako Ohwada‚ Meizi Jiang‚ Koutaro Yokote‚ Isamu Fukamachi‚ Tohru Iseki‚ Hideaki Bujo. Soluble LR11‚ an inhibitor of SDF-1-mediated attachment of HL-60 cells‚ is a potential circulating marker indicating the G-CSF- induced mobilization of hematopoietic stem cells.
Cancer Stem Cell Symposia 2011-3-7 Keystone/USA
Tanaka‚S Ezh2 plays a critical role in the progression of MLL-AF9-induced acute myeloid leukemia
The 53rd American Society of Hematology 2011-12-10 San Diego/USA
Shimizu‚N. Soluble LR11‚ a potential circulating marker indicating the G-CSF-induced mobilization of hematopoietic stem cells‚ is a modulator of G-CSF-mediated migration of HL-60 cells
The 53rd American Society of Hematology 2011-12-10 San Diego/USA
Yokote‚K. Eight years of experience with pitavastatin.
The 27th Mexican Congress of Cardiology 2011-11-21 Puerto Vallarta/Mexico
Kawaguchi‚T Serum soluble LR11 is a promising novel biomarker for B cell lymphoma.
The 53rd American Society of Hematology 2011-11-10 San Diego/USA
